Literature DB >> 35817559

Classical infratentorial superficial siderosis of the central nervous system: pathophysiology, clinical features and management.

Natallia Kharytaniuk1,2,3, Peter Cowley4, Parag Sayal5, Perla Eleftheriou6, Simon F Farmer7, Edgar Chan8, Doris-Eva Bamiou1,2,3, David J Werring9,10.   

Abstract

The term superficial siderosis (SS) is derived from the Greek word 'sideros', meaning iron. It includes two subtypes, distinguished by their anatomical distribution, causes and clinical features: 'classical' infratentorial SS (iSS, which sometimes also affects supratentorial regions) and cortical SS (cSS, which affects only supratentorial regions). This paper considers iSS, a potentially disabling disorder usually associated with very slow persistent or intermittent subarachnoid bleeding from a dural defect, and characterised by progressive hearing and vestibular impairment, ataxia, myelopathy and cognitive dysfunction. The causal dural defect-most often spinal but sometimes in the posterior fossa-typically follows trauma or neurosurgery occurring decades before diagnosis. Increasing recognition of iSS with paramagnetic-sensitive MRI is leading to an unmet clinical need. Given the diagnostic challenges and complex neurological impairments in iSS, we have developed a multidisciplinary approach involving key teams. We discuss pathophysiology, diagnosis and management of iSS, including a proposed clinical care pathway. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  MRI; NEUROSURGERY; SUPERFICIAL SIDEROSIS

Year:  2022        PMID: 35817559     DOI: 10.1136/practneurol-2021-003324

Source DB:  PubMed          Journal:  Pract Neurol        ISSN: 1474-7758


  1 in total

1.  Olfactory dysfunction is common in classical infratentorial superficial siderosis of the central nervous system.

Authors:  Natallia Kharytaniuk; E A Lim; E Chan; M Pavlou; D J Werring; D E Bamiou
Journal:  J Neurol       Date:  2022-08-23       Impact factor: 6.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.